Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10386 in advanced solid tumors
NCT05911464Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-10386 in solid tumor, sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose or Maximum Applicable Dose at 21 days and Objective Response Rate at 12 months. Started Mar 2023; status: recruiting.
02
Drugs
HS-10386
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05911464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911464.